• Pivotal TACTI-004 Phase III trial in 1L NSCLC continues to build momentum
• INSIGHT-003 trial achieves high response rate of 60.8% and 90.2% disease control rate in 1L NSCLC
• TACTI-003 Cohort B achieves excellent median Overall Survival of 17.6 months in 1L HNSCC with CPS <1

Immutep provides an update on its activities for the quarter ended 30 June 2025 (Q4 FY25). The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries. The investigator-initiated INSIGHT-003 trial evaluating efti in combination with KEYTRUDA and chemotherapy as first-line treatment for 1L NSCLC achieved a high 60.8% response rate and 90.2% disease control rate. In patients with TPS <50%, who represent a high unmet need and over two-thirds of the 1L NSCLC population, the triple combination with efti achieved a 59.6% response rate. In the TACTI-003 (KEYNOTE-C34) Cohort B Phase IIb trial, efti in combination with KEYTRUDA achieved an excellent median Overall Survival of 17.6 months in first line head and neck squamous cell carcinoma (1L HNSCC) patients with PD-L1 expression below one (CPS <1). The investigator-initiated EFTISARC-NEO Phase II trial evaluating efti with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. Immutep also reports positive initial efficacy and safety data from the Phase I trial of its autoimmune candidate IMP761. The company is well funded with a strong cash position of A$129.69 million, providing an expected cash reach to the end of CY2026.

Immutep reports a strong cash position of A$129.69 million as at 30 June 2025, which is greater than budgeted and provides an expected cash reach to the end of CY2026.